×

Price is not the only criteria: AstraZeneca chair

10:44 AM ET Mon, 19 May 2014

Execution risk and the disruptive element of Pfizer's offer on AstraZeneca's pipeline were also taken into consideration before rebuffing the U.S. giant, Leif Johansson, chairman at AstraZeneca, tells CNBC.